Generated: September 22, 2017
DrugPatentWatch Database Preview
SCANDONEST L Drug Profile
Which patents cover Scandonest L, and when can generic versions of Scandonest L launch?
is a drug marketed by Deproco and is included in one NDA.
The generic ingredient in SCANDONEST L is levonordefrin; mepivacaine hydrochloride. There are two drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the levonordefrin; mepivacaine hydrochloride profile page.
Summary for Tradename: SCANDONEST L
Pharmacology for Tradename: SCANDONEST L
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.